Overview

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Glimepiride
Metformin
Vildagliptin